Drugs / HDI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00679289 Background | Mar 2008 → Feb 2014 | cutaneous melanoma, metastatic melanoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00679289 ↗ |
| Route | Intravenous | “HDI at a dose of 20 million units (MU)/m administered intravenously for 5 consecutive days per week for the first 4 weeks” PMID 28489678 ↗ Aug 2017 |